NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

| More on:
A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.

Image source: The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have been outperforming this year and delivered very strong returns for shareholders.

Since the start of the year, the private health insurer's shares are up a sizeable 24%.

This compares very favourably to the benchmark ASX 200 index, which is up approximately 6.5% over the same period.

Can NIB shares keep rising?

Unfortunately, the team at Macquarie thinks that the run is coming to an end, particularly given that a new headwind is emerging for one of NIB's businesses.

That headwind is the Department of Health preparing to respond to an Issues Paper assessing the level of commissions paid to third party agents.

The Department of Health is looking at the Overseas Student Health Cover market and is testing three items. Of particular interest to Macquarie is a potential cap on payments to third-party agents for distributing insurance policies to students.

While Macquarie notes that commission caps could make larger university contracts more valuable to NIB, it suspects that it could pressure the business model for agents.

Commenting on this potential headwind, the broker said:

A ~12% commission cap could be an outcome (some arrangements are currently 30%-40%). While insurer margins could increase in the short term, sales driven businesses (not supported by ancillary offerings) could struggle. Notably, NHF relies on sales agents (particularly in India), which could be at risk, while being underweight university contracts. Additionally, as one of the few insurers offering a full product lifecycle, slower sales to Students would negatively impact NHF's higher-margin Workers' policyholders.

We estimate Students represented ~33% / ~20% of Revenue / UOP in NHF's IIHI division in FY24. This would equate to ~2.2% of Group UOP, before accounting for stranded costs and conversion into Workers policies.

Shares tipped to fall

The note reveals that Macquarie has reaffirmed its underperform rating and $5.55 price target on NIB's shares. Based on its current share price of $6.87, this implies potential downside of 19% for investors over the next 12 months.

And while a ~4% dividend yield is expected over the next 12 months, this only limits the total negative return to approximately 15%.

Commenting on its underperform rating, the broker said:

Underperform. With multiple sub-divisions now experiencing operational headwinds, we retain our cautious outlook.

In light of this, investors may want to keep their powder dry for the time being and wait for a better entry point or for its headwinds to clear and tailwinds to emerge.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

young female doctor with digital tablet looking confused.
Healthcare Shares

Will Telix shares drop below $10?

Telix shares are trading in the red again today.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 large-cap healthcare shares just re-rated by experts

What do market analysts think of these mega healthcare companies?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Guess which ASX 200 healthcare share is crashing 22% on Tuesday on European blow

Bad news out of Europe is weighing heavily on this stock today.

Read more »

man with his hand on his chin wondering about the AIM share price
Healthcare Shares

Are CSL shares as a buy, hold, or sell ahead of its results?

Let's see what Bell Potter is saying about this biotech giant ahead of its results.

Read more »

A female scientist sits at a microscope in a Universal Biosensors laboratory smiling while her colleague checks beakers of COVID-19 samples in the background.
Healthcare Shares

This probiotics company has just struck a distribution deal, sending its shares sharply higher

Shares in Biome Australia have jumped after the company announced a distribution deal for its probiotic products in Canada.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Massive capital raise to progress drug trials announced

This raise will set the company up for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

4DMedical shares jump again today. Here's what investors liked

Commercial momentum builds following a busy quarterly update.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

I think the market is wrong about CSL shares

When a world-class business loses tens of billions in value, I think it’s worth asking whether the market has overreacted.

Read more »